Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Grazyna Lietzau"'
Autor:
Fausto Chiazza, Harald Tammen, Hiranya Pintana, Grazyna Lietzau, Massimo Collino, Thomas Nyström, Thomas Klein, Vladimer Darsalia, Cesare Patrone
Publikováno v:
Cardiovascular Diabetology, Vol 17, Iss 1, Pp 1-13 (2018)
Abstract Background Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) are approved drugs for the treatment of hyperglycemia in patients with type 2 diabetes. These effects are mainly mediated by inhibiting endogenous glucagon-like peptide-1 (GLP-1
Externí odkaz:
https://doaj.org/article/8aea2e3d84d74e568768d9f7012ce3f9
Autor:
Vladimer Darsalia, Odd Erik Johansen, Grazyna Lietzau, Thomas Nyström, Thomas Klein, Cesare Patrone
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Cerebral stroke is a leading cause of death and persistent disability of elderly in the world. Although stroke prevention by targeting several risk factors such as diabetes and hypertension has decreased the stroke incidence, the total number of stro
Externí odkaz:
https://doaj.org/article/644eaad974d746899b7d4c74e8260257
Autor:
Shiva Mansouri, Grazyna Lietzau, Mathias Lundberg, David Nathanson, Thomas Nyström, Cesare Patrone
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0156867 (2016)
Hypoglycaemia is a common side-effect of glucose-lowering therapies for type-2 diabetic patients, which may cause cognitive/neurological impairment. Although the effects of hypoglycaemia in the brain have been extensively studied in neurons, how hypo
Externí odkaz:
https://doaj.org/article/bb4dfc8a1f6c4391b6e9a8f737e327f3
Autor:
Grazyna Lietzau, Waldemar Sienkiewicz, Zbigniew Karwacki, Jerzy Dziewiątkowski, Jerzy Kaleczyc, Przemysław Kowiański
Publikováno v:
Molecular Neurobiology.
Statins are lipid-lowering drugs that act by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase, a rate-limiting enzyme in cholesterol biosynthesis. Animal studies have shown neuroprotective effects of statins in cerebral stroke. However, the
Publikováno v:
Folia Morphologica. 80:766-775
The dynamic development of studies on neuroglia in recent years indicates its previously underestimated role in maintaining proper brain function, both in physiological and pathological conditions. The use of modern research methods such as single-ce
Autor:
Grazyna Lietzau, Vladimer Darsalia, Thomas Klein, Camilla Krizhanovskii, Hiranya Pintana, Thomas Nyström, Stelia Ntika, Linda Tracy, Cesare Patrone
Publikováno v:
Cellular and Molecular Neurobiology. 42:1995-2002
Glucagon-like peptide-1 (GLP-1) is a peripheral incretin and centrally active peptide produced in the intestine and nucleus tractus solitarii (NTS), respectively. GLP-1 not only regulates metabolism but also improves cognition and is neuroprotective.
Publikováno v:
Journal of chemical neuroanatomy. 127
Brain injury triggers a complex response involving morphological changes, cellular proliferation, and differentiation of newly formed neuroglial subpopulations. These processes have been extensively studied in animal stroke models with permanent larg
Publikováno v:
ACS Chemical Neuroscience
Olfactory dysfunction could be an early indicator of cognitive decline in type 2 diabetes (T2D). However, whether obesity affects olfaction in people with T2D is unclear. This question needs to be addressed, because most people with T2D are obese. Im
Autor:
Vladimer Darsalia, Thomas Nyström, Grazyna Lietzau, Hiranya Pintana, Fausto Chiazza, Cesare Patrone
Publikováno v:
Cellular and Molecular Neurobiology
Type 2 diabetes (T2D) hampers recovery after stroke, but the underling mechanisms are mostly unknown. In a recently published study (Pintana et al. in Clin Sci (Lond) 133(13):1367–1386, 2019), we showed that impaired recovery in T2D was associated
Autor:
Hans Pettersson, Cesare Patrone, Thomas Nyström, Vladimer Darsalia, Stefania Ceruti, Ana I. Duarte, Jan Kehr, Takashi Yoshitake, Maria P. Abbracchio, Emanuel Candeias, Grazyna Lietzau, Josefin Skogsberg, Thomas Klein, Giulia Magni
Publikováno v:
Neurobiology of Aging. 89:12-23
The nigrostriatal dopaminergic system (NDS) controls motor activity, and its impairment during type 2 diabetes (T2D) progression could increase Parkinson's disease risk in diabetics. If so, whether glycemia regulation prevents this impairment needs t